Author(s)

Noriko Aramaki-Hattori¹, Keisuke Okabe¹, Yoshiaki Sakamoto¹, Shigeki Sakai¹, Tetsu Hayashida², Maiko Takahashi², Tomoko Seki², Yuko Kitagawa², Hiromitsu Jinno³, Kazuo Kishi^1*

¹Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo, Japan.
²Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
³Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.

This single-center, randomized, and controlled intervention study compared an acrylate skin adhesive, Epinexus^TM (Mitsui Chemicals, Inc., Tokyo) with Dermabond Advanced^R (Ethicon, Inc., Somerville, New Jersey). The primary endpoint was cosmetic outcome at 52 weeks after treatment (Manchester Scar Scale), and the secondary endpoints were cosmetic outcome at 4 and 26 weeks after treatment (Manchester Scar Scale), wound closure, and usability. We evaluated 59 patients (29 cases and 30 controls). Failures and adverse events were also evaluated, and 8 adverse events (5 cases and 3 controls) were reported (epidermolysis, n = 4; contact dermatitis, n = 1; eczema, n = 1; and surgical wound dehiscence, n = 2). No difference was observed between groups in cosmetic outcome at 52 and 24 weeks; however, at 4 weeks, cases showed better cosmetic outcome compared with controls. With regard to usability, the treatment duration and application time were significantly longer with Epinexus^TM, and ease of application was significantly better with Dermabond Advanced^R.

Acrylate Skin Adhesive, Single-Center, Comparative Randomized Control Study, Cosmetic Outcome

Aramaki-Hattori, N. , Okabe, K. , Sakamoto, Y. , Sakai, S. , Hayashida, T. , Takahashi, M. , Seki, T. , Kitagawa, Y. , Jinno, H. and Kishi, K. (2018) Efficacy and Safety of the Skin Adhesive EpinexusTM in Surgical Patients. Modern Plastic Surgery, 8, 61-69. doi: 10.4236/mps.2018.84008.